Clinical Trials Sponsored by Horizon Therapeutics Ireland DAC

Total 10 results

Horizon Therapeutics Ireland DAC

Completed

Study to Evaluate HZN-457 in Healthy Volunteers

Healthy

New Zealand
Horizon Therapeutics Ireland DAC

Completed

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (MIRROR RCT)

Gout

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant

Uncontrolled Gout | Kidney Transplant

United States
Horizon Therapeutics Ireland DAC

Completed

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout (MIRROR OL)

Gout

United States
Horizon Therapeutics Ireland DAC

Completed

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Uncontrolled Gout

United States
Hansoh BioMedical R&D Company
Horizon Therapeutics Ireland DAC

Not yet recruiting

A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders

China
Horizon Therapeutics, LLC

Completed

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Urea Cycle Disorder

United States, Spain, Italy, Switzerland
Horizon Therapeutics, LLC

Terminated

Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs) (THRIVE)

Urea Cycle Disorder

United States
Horizon Therapeutics, LLC

Completed

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Urea Cycle Disorder

United States, Canada
Horizon Therapeutics, LLC

Completed

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

Urea Cycle Disorders

United States, Canada

3

Subscribe